Combined Anti-VEGF and Anti-CTLA-4 therapy elicits humoral immunity to galectin-1 which is associated with favorable clinical outcomes

Cancer Immunology Research

Volumn 5, Issue 6, 2017, Pages 446-454

  Wu, Xinqi ^a   Li, Jingjing ^a   Connolly, Erin M ^a   Liao, Xiaoyun ^a   Ouyang, Jing ^a   Giobbie Hurder, Anita ^a   Lawrence, Donald ^b   Mcdermott, David ^c   Murphy, George ^d   Zhou, Jun ^a   Piesche, Matthias ^e   Dranoff, Glenn ^f   Rodig, Scott ^a,d   Shipp, Margaret ^a   Hodi, F Stephen ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSIDAD CATÓLICA DEL MAULE   (Chile)

^f NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BEVACIZUMAB; CD45 ANTIGEN; GALECTIN 1; IPILIMUMAB; PEMBROLIZUMAB; ANTINEOPLASTIC AGENT; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; LGALS1 PROTEIN, HUMAN; PTPRC PROTEIN, HUMAN; RECEPTOR TYPE TYROSINE PROTEIN PHOSPHATASE C; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL OUTCOME; HUMAN; HUMORAL IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; METASTATIC MELANOMA; OVERALL SURVIVAL; PROTEIN BINDING; PROTEIN MICROARRAY; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DRUG EFFECTS; IMMUNOLOGY; MELANOMA; PHASE 1 CLINICAL TRIAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CTLA-4 ANTIGEN; GALECTIN 1; HUMANS; IMMUNITY, HUMORAL; IPILIMUMAB; LEUKOCYTE COMMON ANTIGENS; MELANOMA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85020633638     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-16-0385     Document Type: Article

References (45)

1. Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol 2006;90:297-339.
2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survivalwith ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
3. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26.
4. Yuan J, Zhou J, Dong Z, Tandon S, Kuk D, Panageas KS, et al. Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 2014;2:127-32.
5. Ohm JE, Carbone DP. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res 2001;23:263-72.
6. Oyama T, Ran S, Ishida T, Nadaf S, Kerr L, Carbone DP, et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol 1998;160:1224-32.
7. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012;12:237-51.
8. Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 2010;70:6171-80.
9. Huang H, Langenkamp E, Georganaki M, Loskog A, Fuchs PF, Dieterich LC, et al. VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition ofNF-kappaB-induced endothelial activation. FASEB J 2015;29:227-38.
10. Schoenfeld J, Jinushi M, Nakazaki Y, Wiener D, Park J, Soiffer R, et al. Active immunotherapy induces antibody responses that target tumor angiogenesis. Cancer Res 2010;70:10150-60.
11. Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2014;2:632-42.
12. Sage PT, Paterson AM, Lovitch SB, Sharpe AH. The coinhibitory receptor CTLA-4 controls B cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells. Immunity 2014;41: 1026-39.
13. Sage PT, Sharpe AH. T follicular regulatory cells in the regulation of B cell responses. Trends Immunol 2015;36:410-8.
14. Wu X, Giobbie-Hurder A, Liao X, Lawrence D, McDermott D, Zhou J, et al. VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma. Cancer Immunol Res 2016;4:858-68.
15. Wu X, Giobbie-Hurder A, Liao X, Connelly C, Connolly EM, Li J, et al. Angiopoietin-2 as a biomarker and target for immune checkpoint therapy. Cancer Immunol Res 2017;5:17-28.
16. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 2003;100:4712-7.
17. Jinushi M, Hodi FS, Dranoff G. Therapy-induced antibodies toMHCclass I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc Natl Acad Sci U S A 2006;103:9190-5.
18. Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, Serova M, Neuzillet C, Albert S, et al. Unraveling galectin-1 as a novel therapeutic target for cancer. Cancer Treat Rev 2014;40:307-19.
19. Camby I, Le Mercier, M, Lefranc F, Kiss R. Galectin-1: A small protein with major functions. Glycobiology 2006;16:137R-57R.
20. Braeuer RR, Shoshan E, Kamiya T, Bar-Eli M. The sweet and bitter sides of galectins in melanoma progression. Pigment Cell Melanoma Res 2012;25:592-601.
21. Thijssen VL, Hulsmans S, Griffioen AW. The galectin profile of the endothelium: Altered expression and localization in activated and tumor endothelial cells. Am J Pathol 2008;172:545-53.
22. Croci DO, Salatino M, Rubinstein N, Cerliani JP, Cavallin LE, Leung HJ, et al. Disrupting galectin-1 interactions with N-glycans suppresses hypoxiadriven angiogenesis and tumorigenesis in Kaposi's sarcoma. J Exp Med 2012;209:1985-2000.
23. Thijssen VL, Postel R, Brandwijk RJ, Dings RP, Nesmelova I, Satijn S, et al. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci U S A 2006;103:15975-80.
24. He J, Baum LG. Presentation of galectin-1 by extracellular matrix triggers T cell death. J Biol Chem 2004;279:4705-12.
25. Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilarregui JM, Bravo A, et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumorimmune privilege. Cancer Cell 2004;5:241-51.
26. Dalotto-Moreno T, Croci DO, Cerliani JP, Martinez-Allo VC, Dergan-Dylon S, Mendez-Huergo SP, et al. Targeting galectin-1 overcomes breast cancerassociated immunosuppression and prevents metastatic disease. Cancer Res 2013;73:1107-17.
27. Croci DO, Cerliani JP, Dalotto-Moreno T, Mendez-Huergo SP, Mascanfroni ID, Dergan-Dylon S, et al. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell 2014;156:744-58.
28. Mathieu V, de Lassalle, EM, Toelen J, Mohr T, Bellahcene A, Van Goietsenoven, G, et al. Galectin-1 in melanoma biology and related neo-angiogenesis processes. J Invest Dermatol 2012;132:2245-54.
29. Ouyang J, Plutschow A, Pogge von Strandmann E, Reiners KS, Ponader S, Rabinovich GA, et al. Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphoma. Blood 2013;121:3431-3.
30. Ouyang J, Juszczynski P, Rodig SJ, Green MR, O'Donnell E, Currie T, et al. Viral induction and targeted inhibition of galectin-1 in EBV posttransplant lymphoproliferative disorders. Blood 2011;117:4315-22.
31. Contal C, O'Quigley J. An application of changepoint methods in studying the effect of age on survival in breast cancer. Computational Statistics and Data Analysis 1999;30:253-70.
32. Sage PT, Francisco LM, Carman CV, Sharpe AH. The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood. Nat Immunol 2013;14:152-61.
33. Sage PT, Sharpe AH. T follicular regulatory cells. Immunol Rev 2016; 271:246-59.
34. Perillo NL, Pace KE, Seilhamer JJ, Baum LG. Apoptosis of T cells mediated by galectin-1. Nature 1995;378:736-9.
35. Pace KE, Lee C, Stewart PL, Baum LG. Restricted receptor segregation into membrane microdomains occurs on human T cells during apoptosis induced by galectin-1. J Immunol 1999;163:3801-11.
36. Nguyen JT, Evans DP, Galvan M, Pace KE, Leitenberg D, Bui TN, et al. CD45 modulates galectin-1-induced T cell death: regulation by expression of core 2 O-glycans. J Immunol 2001;167:5697-707.
37. Stillman BN, Hsu DK, Pang M, Brewer CF, Johnson P, Liu FT, et al. Galectin- 3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death. J Immunol 2006;176:778-89.
38. Perillo NL, Uittenbogaart CH, Nguyen JT, Baum LG. Galectin-1, an endogenous lectin produced by thymic epithelial cells, induces apoptosis of human thymocytes. J Exp Med 1997;185:1851-8.
39. Garin MI, Chu CC, Golshayan D, Cernuda-Morollon E, Wait R, Lechler RI. Galectin-1: A key effector of regulation mediated by CD4CD25 T cells. Blood 2007;109:2058-65.
40. Rabinovich GA, Ilarregui JM. Conveying glycan information into T-cell homeostatic programs: A challenging role for galectin-1 in inflammatory and tumor microenvironments. Immunol Rev 2009;230:144-59.
41. Cedeno-Laurent F, Opperman MJ, Barthel SR, Hays D, Schatton T, Zhan Q, et al. Metabolic inhibition of galectin-1-binding carbohydrates accentuates antitumor immunity. J Invest Dermatol 2012;132:410-20.
42. Toscano MA, Bianco GA, Ilarregui JM, Croci DO, Correale J, Hernandez JD, et al. Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat Immunol 2007;8:825-34.
43. Hsieh H, Ying NW, Wu MH, Chiang WF, Hsu CL, Wong TY, et al. Galectin-1, a novel ligand of neuropilin-1, activates VEGFR-2 signaling and modulates the migration of vascular endothelial cells. Oncogene 2008;27:3746-53.
44. Laderach DJ, Gentilini LD, Giribaldi L, Delgado VC, Nugnes L, Croci DO, et al. A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease. Cancer Res 2013;73:86-96.
45. Thijssen VL, Poirier F, Baum LG, Griffioen AW. Galectins in the tumor endothelium: opportunities for combined cancer therapy. Blood 2007;110:2819-27.